LXEO Overview

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Wall Street analysts forecast LXEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXEO is20.29 USD with a low forecast of 13.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lexeo Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

Lexeo Therapeutics Inc. EPS for the last quarter amounts to -0.33 USD, decreased -62.92

Lexeo Therapeutics Inc (LXEO) has 72 emplpoyees as of March 11 2026.

Today LXEO has the market capitalization of 525.51M USD.